OBJECTIVES: Stage III melanoma is associated with an increased risk of recurrence and death. Complete surgical resection remains the best chance for cure. Unfortunately, no adjuvant therapy has demonstrated a consistent improvement in melanoma-specific survival (MSS). We hypothesize that adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF) may improve clinical outcomes. PATIENTS AND METHODS: Retrospective cohort study of 317 surgically resected stage III melanoma patients managed with observation or adjuvant GM-CSF at a single institution from 2001 to 2010. RESULTS: Of the 317 stage III patients, 165 (52%) were observed and 152 (48%) were treated with GM-CSF, with a median follow-up of 34 months. Patients treated with GM-CSF tended to be younger (P < 0.0001), had more advanced stage disease (P = 0.002), and were more likely to have had a recurrence before initiation of adjuvant therapy than the observation group (P < 0.0001). Adjuvant GM-CSF seemed to be associated with improved MSS, but this did not reach statistical significance (P = 0.08). Patients with stage IIIC melanoma derived a substantial benefit from adjuvant GM-CSF, with a 52% risk reduction in melanoma-specific death (hazard ratio 0.48; 95% confidence interval, 0.27-0.87; P = 0.02). CONCLUSIONS: Despite selecting patients with more advanced stage and a higher incidence of regional relapse, adjuvant GM-CSF was associated with an improved MSS but not disease-free survival in patients with stage IIIC disease. In patients not otherwise eligible for clinical trials, adjuvant GM-CSF treatment is a reasonable option for individuals with resected high-risk melanoma.
OBJECTIVES:Stage III melanoma is associated with an increased risk of recurrence and death. Complete surgical resection remains the best chance for cure. Unfortunately, no adjuvant therapy has demonstrated a consistent improvement in melanoma-specific survival (MSS). We hypothesize that adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF) may improve clinical outcomes. PATIENTS AND METHODS: Retrospective cohort study of 317 surgically resected stage III melanomapatients managed with observation or adjuvant GM-CSF at a single institution from 2001 to 2010. RESULTS: Of the 317 stage III patients, 165 (52%) were observed and 152 (48%) were treated with GM-CSF, with a median follow-up of 34 months. Patients treated with GM-CSF tended to be younger (P < 0.0001), had more advanced stage disease (P = 0.002), and were more likely to have had a recurrence before initiation of adjuvant therapy than the observation group (P < 0.0001). Adjuvant GM-CSF seemed to be associated with improved MSS, but this did not reach statistical significance (P = 0.08). Patients with stage IIIC melanoma derived a substantial benefit from adjuvant GM-CSF, with a 52% risk reduction in melanoma-specific death (hazard ratio 0.48; 95% confidence interval, 0.27-0.87; P = 0.02). CONCLUSIONS: Despite selecting patients with more advanced stage and a higher incidence of regional relapse, adjuvant GM-CSF was associated with an improved MSS but not disease-free survival in patients with stage IIIC disease. In patients not otherwise eligible for clinical trials, adjuvant GM-CSF treatment is a reasonable option for individuals with resected high-risk melanoma.
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Matthew S Block; Vera J Suman; Wendy K Nevala; Lisa A Kottschade; Edward T Creagan; Judith S Kaur; Jorge Fernando Quevedo; Robert R McWilliams; Svetomir N Markovic Journal: Melanoma Res Date: 2011-10 Impact factor: 3.599
Authors: E George Elias; John L Zapas; Edward C McCarron; Sandra L Beam; Joanne H Hasskamp; W Joel Culpepper Journal: Cancer Biother Radiopharm Date: 2008-06 Impact factor: 3.099
Authors: Lynn E Spitler; Robert W Weber; Robert E Allen; John Meyer; Scott Cruickshank; Edeltraut Garbe; Hui-Yi Lin; Seng-jaw Soong Journal: J Immunother Date: 2009 Jul-Aug Impact factor: 4.456
Authors: Nathaniel H Fleming; Jiaying Tian; Eleazar Vega-Saenz de Miera; Heidi Gold; Farbod Darvishian; Anna C Pavlick; Russell S Berman; Richard L Shapiro; David Polsky; Iman Osman Journal: Oncology Date: 2013-08-30 Impact factor: 2.935
Authors: David H Lawson; Sandra Lee; Fengmin Zhao; Ahmad A Tarhini; Kim A Margolin; Marc S Ernstoff; Michael B Atkins; Gary I Cohen; Theresa L Whiteside; Lisa H Butterfield; John M Kirkwood Journal: J Clin Oncol Date: 2015-09-08 Impact factor: 44.544
Authors: Serena S Kwek; James Kahn; Samantha K Greaney; Jera Lewis; Edward Cha; Li Zhang; Robert W Weber; Lonnie Leonard; Svetomir N Markovic; Lawrence Fong; Lynn E Spitler Journal: Oncoimmunology Date: 2015-10-29 Impact factor: 8.110
Authors: Lynn E Spitler; Huynh Cao; Timo Piironen; Theresa L Whiteside; Robert W Weber; Scott Cruickshank Journal: Am J Clin Oncol Date: 2017-04 Impact factor: 2.339
Authors: Alexander M Aliper; Victoria P Frieden-Korovkina; Anton Buzdin; Sergey A Roumiantsev; Alex Zhavoronkov Journal: Cancer Med Date: 2014-04-02 Impact factor: 4.452
Authors: Christoph Hoeller; Olivier Michielin; Paolo A Ascierto; Zsolt Szabo; Christian U Blank Journal: Cancer Immunol Immunother Date: 2016-07-02 Impact factor: 6.968